Duke University & Allergan v. Sandoz: Defendant wins on patent invalidity after 8-year Colorado litigation
Duke University and Allergan Sales, LLC sued Sandoz, Inc. in the Colorado District Court for infringement of US9579270B2, covering non-naturally occurring prostaglandin compositions for hair loss treatment. After nearly 2,973 days of litigation, Senior District Judge Raymond P. Moore entered final judgment for Sandoz, finding Claim 30 of the asserted patent invalid for lack of written description — and awarding Sandoz $651,986 in costs.
Eight years of prostaglandin patent litigation ends in Sandoz victory
Duke University and Allergan Sales, LLC filed suit against Sandoz, Inc. on April 26, 2018 in the U.S. District Court for the District of Colorado (Case No. 1:18-cv-00997). The plaintiffs asserted US9579270B2, a patent directed to compositions and methods for treating hair loss using non-naturally occurring prostaglandins. The case remained active for 2,973 days — nearly eight and a quarter years — before final resolution.
The recorded basis of termination is judgment on the merits for the defendant. On June 16, 2026, Senior District Judge Raymond P. Moore directed entry of Final Judgment pursuant to Fed. R. Civ. P. 58(b). The court ordered that Claim 30 of the '270 patent is invalid for lack of written description under 35 U.S.C. § 112, and entered judgment against plaintiffs and in favor of Sandoz on all of plaintiffs' claims. Sandoz was awarded $651,986.00 in costs, payable by plaintiffs within 50 days of the clerk's taxing order; each party was ordered to bear its own attorneys' fees.
The duration — nearly a decade from filing to final judgment — is notable even by the standards of complex ANDA-adjacent pharmaceutical patent disputes. The written-description invalidity finding under § 112 suggests the court found the specification of US9579270B2 did not adequately support the scope of Claim 30 as filed. What specific prosecution history, claim construction rulings, or expert disputes drove that conclusion is not fully disclosed in the available public record of the final judgment entry.
See Complete Case & Patent Analysis →Filing to Judgment on the merits for Defendant in 2973 days
2,973 days — one of the longest first-instance patent cases in the District of Colorado in recent years
US9579270B2 — Non-naturally occurring prostaglandin hair loss compositions
Any company developing, manufacturing, or commercialising non-naturally occurring prostaglandin formulations for hair loss treatment should consider an FTO analysis against US9579270B2 and its patent family. While Claim 30 has been invalidated on the merits, other claims of the patent and any related continuations or divisionals may still present infringement risk. The Colorado judgment does not automatically clear the entire claim set.
Official order — verbatim text
The Final Judgment entered June 16, 2026 reflects a merits determination by Senior District Judge Raymond P. Moore following an appellate cycle referenced in the Order Directing the Clerk of the Court to Award Costs and Enter Judgment after Appeal (Doc. 367). The court's holding that Claim 30 of US9579270B2 is invalid for lack of written description under 35 U.S.C. § 112 is a substantive invalidity ruling — not a procedural dismissal — and carries the full preclusive weight of a final judgment on the merits. Judgment was entered against plaintiffs on all claims, and Sandoz recovered $651,986 in costs.
Judgment for Sandoz: what the invalidity ruling means for both parties
Claim 30 invalidated for lack of written description under § 112
Under 35 U.S.C. § 112, a patent claim is invalid if the specification does not adequately describe the claimed invention to demonstrate the inventor possessed it. Here, the court found Claim 30 of US9579270B2 failed that standard. A merits judgment on invalidity is binding and extinguishes that claim's enforceability — it is not merely a procedural dismissal.
Invalidity — § 112 written descriptionAllergan and Duke lose enforceability of Claim 30 against Sandoz
With judgment entered against all of plaintiffs' claims, Duke University and Allergan cannot enforce Claim 30 of US9579270B2 against Sandoz in this action. The invalidity finding — rendered on the merits — also has potential estoppel implications for future enforcement of that claim against other parties, though the precise scope depends on appellate proceedings the available record does not disclose.
Claim 30 — unenforceable against SandozSandoz prevails on all claims and recovers $651,986 in costs
Sandoz secured a full merits victory: judgment in its favor on every claim asserted by plaintiffs, plus a costs award of $651,986 payable by the plaintiffs within 50 days of the clerk's taxing order. Each party bears its own attorneys' fees. The costs award signals a substantial litigation burden Sandoz successfully shifted back to the plaintiffs.
Full defense verdict + cost recoveryInvalidity ruling creates clearance signal for prostaglandin hair-loss generics
A court-entered invalidity judgment on Claim 30 of US9579270B2 is a meaningful freedom-to-operate signal for other generic and specialty pharma companies working in non-naturally occurring prostaglandin formulations for hair loss. However, companies should confirm whether other claims of the patent or related family members remain in force before relying on this outcome as blanket clearance.
FTO signal — prostaglandin hair loss spaceFull party and counsel information
| Role | Name | Type | Detail |
|---|---|---|---|
| Plaintiff | Duke University | Company | /Search in Eureka ↗ |
| Co-Plaintiff | Allergan Sales, LLC | Company | Search in Eureka ↗ |
| Defendant | Sandoz, Inc. | Company | /Search in Eureka ↗ |
| Plaintiff counsel | Caitlin Patricia Hogan | Attorney | Counsel for Duke UniversitySearch in Eureka ↗ |
| Plaintiff counsel | Carolyn S. Wall | Attorney | Counsel for Duke UniversitySearch in Eureka ↗ |
| Plaintiff counsel | Chuan Cheng | Attorney | Counsel for Duke UniversitySearch in Eureka ↗ |
| Plaintiff counsel | Deanna Jean Reichel | Attorney | Counsel for Duke UniversitySearch in Eureka ↗ |
| Plaintiff counsel | Elizabeth Marjorie Flanagan | Attorney | Counsel for Duke UniversitySearch in Eureka ↗ |
| Plaintiff counsel | Eric Shaun Hochstadt | Attorney | Counsel for Duke UniversitySearch in Eureka ↗ |
| Plaintiff counsel | Hassen Amir Sayeed | Attorney | Counsel for Duke UniversitySearch in Eureka ↗ |
| Plaintiff counsel | Jacob A. Rey | Attorney | Counsel for Duke UniversitySearch in Eureka ↗ |
| Plaintiff counsel | James Y. Li | Attorney | Counsel for Duke UniversitySearch in Eureka ↗ |
| Plaintiff counsel | Jing Ying Zhao | Attorney | Counsel for Duke UniversitySearch in Eureka ↗ |
| Plaintiff counsel | John M. Farrell | Attorney | Counsel for Duke UniversitySearch in Eureka ↗ |
| Plaintiff counsel | Jonathan E. Singer | Attorney | Counsel for Duke UniversitySearch in Eureka ↗ |
| Plaintiff counsel | Kathryn A. Reilly | Attorney | Counsel for Duke UniversitySearch in Eureka ↗ |
| Plaintiff counsel | Kelly A. Del Dotto | Attorney | Counsel for Duke UniversitySearch in Eureka ↗ |
| Plaintiff counsel | Lindsay H. Autz | Attorney | Counsel for Duke UniversitySearch in Eureka ↗ |
| Plaintiff counsel | Lisa B. Pensabene | Attorney | Counsel for Duke UniversitySearch in Eureka ↗ |
| Plaintiff counsel | Michael Patrick Dulin | Attorney | Counsel for Duke UniversitySearch in Eureka ↗ |
| Plaintiff counsel | Phillip Wagner Goter | Attorney | Counsel for Duke UniversitySearch in Eureka ↗ |
| Plaintiff counsel | Susan E. Morrison | Attorney | Counsel for Duke UniversitySearch in Eureka ↗ |
| Plaintiff counsel | Timothy S. Durst | Attorney | Counsel for Duke UniversitySearch in Eureka ↗ |
| Plaintiff law firm | Fish & Richardson PC | Law Firm | Representing Duke UniversitySearch in Eureka ↗ |
| Plaintiff law firm | Greenberg Traurig LLP | Law Firm | Representing Duke UniversitySearch in Eureka ↗ |
| Plaintiff law firm | O'Melveny & Myers LLP | Law Firm | Representing Duke UniversitySearch in Eureka ↗ |
| Plaintiff law firm | Weil, Gotshal & Manges LLP | Law Firm | Representing Duke UniversitySearch in Eureka ↗ |
| Plaintiff law firm | Wheeler Trigg O'Donnell LLP | Law Firm | Representing Duke UniversitySearch in Eureka ↗ |
| Defendant counsel | Candice Jaesun Kwark | Attorney | Counsel for Sandoz, Inc.Search in Eureka ↗ |
| Defendant counsel | Daniel Shaw Young | Attorney | Counsel for Sandoz, Inc.Search in Eureka ↗ |
| Defendant counsel | Gerard J. Cedrone | Attorney | Counsel for Sandoz, Inc.Search in Eureka ↗ |
| Defendant counsel | Gretchen Porter Miller | Attorney | Counsel for Sandoz, Inc.Search in Eureka ↗ |
| Defendant counsel | John Lloyd Abramic | Attorney | Counsel for Sandoz, Inc.Search in Eureka ↗ |
| Defendant counsel | Katherine H. Tellez | Attorney | Counsel for Sandoz, Inc.Search in Eureka ↗ |
| Defendant counsel | Kathryn Lenhart Bohmann | Attorney | Counsel for Sandoz, Inc.Search in Eureka ↗ |
| Defendant counsel | Lillian Anne Wallace | Attorney | Counsel for Sandoz, Inc.Search in Eureka ↗ |
| Defendant counsel | Matthew M. Zuziak | Attorney | Counsel for Sandoz, Inc.Search in Eureka ↗ |
| Defendant counsel | Richard Kent Kornfeld | Attorney | Counsel for Sandoz, Inc.Search in Eureka ↗ |
| Defendant counsel | Robert F. Kappers | Attorney | Counsel for Sandoz, Inc.Search in Eureka ↗ |
| Defendant counsel | Ryann Morgan Muir | Attorney | Counsel for Sandoz, Inc.Search in Eureka ↗ |
| Defendant counsel | Thomas J. Filarski | Attorney | Counsel for Sandoz, Inc.Search in Eureka ↗ |
| Defendant counsel | Tyler Doh | Attorney | Counsel for Sandoz, Inc.Search in Eureka ↗ |
| Defendant counsel | Vishal Gupta | Attorney | Counsel for Sandoz, Inc.Search in Eureka ↗ |
| Defendant counsel | William McGinley Jay | Attorney | Counsel for Sandoz, Inc.Search in Eureka ↗ |
| Defendant law firm | Goodwin Procter LLP | Law Firm | Representing Sandoz, Inc.Search in Eureka ↗ |
| Defendant law firm | Massachusetts Attorney General's Office | Law Firm | Representing Sandoz, Inc.Search in Eureka ↗ |
| Defendant law firm | Nixon Peabody LLP | Law Firm | Representing Sandoz, Inc.Search in Eureka ↗ |
| Defendant law firm | Quarles & Brady LLP | Law Firm | Representing Sandoz, Inc.Search in Eureka ↗ |
| Defendant law firm | Recht & Kornfeld PC | Law Firm | Representing Sandoz, Inc.Search in Eureka ↗ |
| Defendant law firm | Steptoe & Johnson PLLC | Law Firm | Representing Sandoz, Inc.Search in Eureka ↗ |
| Defendant law firm | Steptoe, LLP | Law Firm | Representing Sandoz, Inc.Search in Eureka ↗ |
| Presiding judge | Judge N/A | Judge | Colorado District CourtSearch in Eureka ↗ |
R&D signals in the prostaglandin hair-loss patent space
Forward-looking patent and R&D intelligence derived from the Duke University, Allergan, and Sandoz dispute over non-naturally occurring prostaglandin hair-loss compositions.
Duke & Allergan's prostaglandin patent filing activity post-litigation
Duke University and Allergan's co-prosecution of US9579270B2 reflects an academic-commercial patent development model in dermatological pharmacology. Monitoring their joint and individual prosecution activity for continuation filings, divisionals, or new applications in the prostaglandin space can reveal whether they are rebuilding written-description support or pivoting to adjacent therapeutic mechanisms.
Allergan + Duke prostaglandin filingsFiling trends in non-naturally occurring prostaglandin formulations for alopecia
The prostaglandin pathway — particularly synthetic analogues targeting hair follicle biology — is an active area of dermatological patent activity. Following this litigation outcome, competitors and research institutions may accelerate filings in adjacent prostaglandin receptor subtypes or alternative lipid mediator approaches that design around the invalidated claim scope of the '270 patent.
Prostaglandin alopecia patent trendsSandoz's patent and IP position in dermatological generics
Sandoz's sustained defense and ultimate victory in this nearly decade-long case demonstrates a willingness to invest heavily in invalidating originator patents blocking generic entry in specialty dermatology. Reviewing Sandoz's own patent filings and inter partes review petitions in adjacent therapeutic areas can signal where the company anticipates its next generic development priorities.
Sandoz dermatology generic IP strategyAdjacent R&D white space near invalidated prostaglandin claim scope
The written-description invalidity of Claim 30 may open claim scope around specific non-naturally occurring prostaglandin structures or delivery methods that were nominally covered but not adequately described in the '270 specification. Innovators and generic companies alike can use PatSnap Eureka to identify unclaimed or weakly-claimed structural space adjacent to US9579270B2 for new filings or formulation design.
Prostaglandin claim white spaceSimilar prostaglandin and dermatology patent infringement cases
Explore comparable pharmaceutical patent infringement actions involving prostaglandin formulations and § 112 written-description challenges in U.S. district courts.
What this case signals for the pharmaceutical patent IP landscape
A hard-fought § 112 invalidity win for Sandoz after nearly a decade reshapes risk calculus for prostaglandin hair-loss IP portfolios.
Written-description attacks remain a viable long-game strategy against pharma patents
Sandoz's § 112 written-description defense ultimately prevailed after nearly 2,973 days of litigation. This outcome reinforces that generic defendants willing to sustain prolonged district court battles can successfully challenge patent claims on specification-sufficiency grounds, even when the originator holds university co-inventorship credentials.
Cost awards in long pharmaceutical cases can reach significant six-figure sums
The $651,986 costs award to Sandoz illustrates that prevailing defendants in complex, multi-year pharmaceutical patent disputes can recover substantial litigation expenses. Plaintiffs in ANDA-adjacent or pharma patent cases should model adverse cost exposure as part of pre-litigation risk assessment, even where attorneys' fees are not at stake.
Duke v Sandoz — key questions answered
The Colorado District Court entered final judgment on June 16, 2026 in favor of defendant Sandoz, Inc. on all of plaintiffs' claims. Claim 30 of US9579270B2 was held invalid for lack of written description under 35 U.S.C. § 112. Sandoz was awarded $651,986 in costs; each party bears its own attorneys' fees.
The court found Claim 30 of US9579270B2 invalid for lack of written description under 35 U.S.C. § 112. This means the court determined the patent specification did not adequately describe the claimed invention to demonstrate that the inventors possessed it at the time of filing. The specific claim construction and expert findings underlying this conclusion are not fully detailed in the final judgment text.
The plaintiffs asserted US9579270B2 (application number US14/958334), directed to compositions and methods for treating hair loss using non-naturally occurring prostaglandins. The case involved Claim 30 of that patent as the focal point of the invalidity determination.
The case was filed on April 26, 2018 and closed on June 16, 2026 — a duration of 2,973 days, or approximately eight years and two months. This places it among the longer first-instance patent litigations recorded in the District of Colorado.
The court awarded Sandoz $651,986.00 in costs incurred in the action, to be paid by plaintiffs Duke University and Allergan Sales, LLC within 50 days of the clerk's taxing order. The court separately ordered that each party shall pay its own attorneys' fees — meaning no fee-shifting award was made to either side.
This page is compiled from public court dockets and third-party patent and litigation data via PatSnap Eureka, and is provided for general informational purposes only. The information shown — including party names, patent and application numbers, dates, case status, outcomes, and any analysis — may be incomplete, may not reflect the most recent filings or legal status, and may contain errors or omissions. Verify all details against official court records (for example, PACER) and the relevant patent office before relying on them.
Nothing on this page constitutes legal advice or a legal opinion on the validity, infringement, enforceability, or scope of any patent or case, and no attorney‑client relationship is created by its use. Any description of an outcome (such as a dismissal, settlement, or consent judgment) is a general summary, not a legal determination. All patents, trademarks, and company or law‑firm names are the property of their respective owners. PatSnap makes no warranty as to the accuracy or completeness of this content and disclaims, to the fullest extent permitted by law, all liability for reliance on it. For advice on a specific matter, consult qualified legal counsel.
PatSnap Eureka searches patents and litigation data to answer instantly.